14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
SYRE vs MANE: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
SYRE Overall Winner
6-Pillar Tally: SYRE 2 – 1 MANE (3 Tie)
Matrix Metrics: SYRE 8 – 0 MANE
As of Nov 16, 2026, Spyre Therapeutics, Inc. (SYRE) is the stronger overall head-to-head candidate over MANE (MANE) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). SYRE carries a Unified Composite Score of 44.4/100 (HOLD) at $99.37 (N/M Forward P/E, 0.0% operating margin), whereas MANE carries 38.1/100 (SELL) at $128.05 (N/M Forward P/E, N/A operating margin).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SYRE vs MANE. Trailing 12-month operating profitability (SYRE 0.0% vs MANE N/A) and valuation multiples (SYRE N/M vs MANE N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $9.9B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
MANE Moat ProfileCyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ SYRE vs MANE Key Questions & Quantitative Answers
As of Nov 16, 2026, Spyre Therapeutics, Inc. (SYRE) is the stronger overall head-to-head candidate over MANE (MANE) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). SYRE carries a Unified Composite Score of 44.4/100 (HOLD) at $99.37 (N/M Forward P/E, 0.0% operating margin), whereas MANE carries 38.1/100 (SELL) at $128.05 (N/M Forward P/E, N/A operating margin). Technically, SYRE sits in a Neutral phase (RSI 53.5, UNCLASSIFIED options structure) and MANE sits in a Neutral phase (RSI 47.0, UNCLASSIFIED options structure).
SYRE leads the Growth & Scale pillar: SYRE posts +0.0% YoY revenue growth and -99.7% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with MANE at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, SYRE generates N/A in USD-normalized revenue versus N/A for MANE. In operating R&D and SG&A reinvestment, SYRE deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MANE.
SYRE and MANE trade at balanced relative valuation multiples. SYRE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas MANE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SYRE (-35.0% ROE) versus MANE (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, SYRE carries 87.9% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.74β · 59% Vol realized risk). By comparison, MANE carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.28β · 80% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.